Introduction
============

There are numerous hemodynamic changes that occur during pregnancy. For example, blood pressure decreases mid-pregnancy despite considerable expansion of blood volume and increased cardiac output (Gordon, [@B18]). The relatively low blood pressure in the face of increased plasma volume is likely due to reduced peripheral vascular resistance (Clapp and Capeless, [@B15]) and adaptation of the systemic vasculature to pregnancy that includes decreased responsiveness to vasoconstrictors (Parent et al., [@B29]; Pascoal et al., [@B30]), decreased sympathetic vasoconstriction (Ralevic and Burnstock, [@B31]), diminished myogenic tone (Learmont et al., [@B23]), and changes in vessel wall composition (Mackey et al., [@B26]). In addition, decreased vascular resistance increases blood flow in several organs during pregnancy, including renal and uterine circulations (Palmer et al., [@B28]; Carlin and Alfirevic, [@B7]). However, despite substantial hemodynamic changes in systemic and other organs during pregnancy, vascular resistance and blood flow in the brain appears to be unchanged (Williams and Wilson, [@B40]; Cipolla and Bullinger, [@B10]). Unlike systemic, renal, cardiac and uterine circulations where substantial hemodynamic changes are essential to accommodate increased blood volume and flow during pregnancy, the lack of hemodynamic changes in the brain is likely important in an organ that relies mainly on oxidative metabolism and needs relatively constant blood flow. Thus, it is possible that the adaptation of the cerebral circulation to pregnancy is to maintain normal vascular resistance and flow in the face of substantial changes in hemodynamics in other organ systems.

Despite apparently unchanged vascular resistance and blood flow in the brain (Williams and Wilson, [@B40]; Cipolla and Bullinger, [@B10]), there are considerable changes in the cerebral vasculature during pregnancy. For example, endothelium-derived hyperpolarizing factor-mediated dilation is lost whereas nitric oxide (NO) is prominent in cerebral arteries during pregnancy (Cipolla et al., [@B14]). In addition, cerebral arteries appear to adapt to the large amount of hormones produced during pregnancy as the constricting influence of pregnant plasma is normalized in cerebral arteries from pregnant rats (Amburgey et al., [@B1]). Further, cerebral (pial) arteries force dilatate at lower pressures during pregnancy (Cipolla et al., [@B14]). Pregnancy also appears to have a significant effect on hypertensive remodeling in cerebral vasculature. Pregnancy reverses and inhibits inward remodeling associated with hypertension, an effect that may maintain normal vascular resistance and blood flow during elevated blood pressure (Cipolla et al., [@B11], [@B10]). Together, these adaptations may have an important protective role in the brain and contribute to the unchanged vascular resistance and blood flow during normal pregnancy.

Although it appears the cerebral circulation adapts to pregnancy, the underlying mechanism by which this occurs is not clear. Peroxisome proliferator-activated receptor-γ (PPARγ), a nuclear receptor transcription factor, regulates the transcription of target genes involved in adipogenesis, glucose homeostasis, and lipid metabolism (Berger et al., [@B5]). The role of PPARγ has also been implicated in pregnancy. PPARγ is highly activated during pregnancy (Waite et al., [@B37]) and has an important role in maternal metabolism, placental development, and trophoblast invasion (Wieser et al., [@B39]). Recently, the pleiotropic effect of PPARγ has been shown in the cardiovascular system. PPARγ appears to have direct protective effects including anti-hypertensive, anti-inflammatory, and anti-atherosclerotic properties in the vasculature (Hsueh and Law, [@B21]; Robinson and Grieve, [@B32]; Sigmund, [@B33]). These protective effects of PPARγ may be more prominent in the cerebral circulation. For example, genetic interference of PPARγ function reduced the vasodilatory response to ACh in basilar arteries, but not in aorta (Beyer et al., [@B6]). The same study also showed that interference of PPARγ function causes hypertrophic inward remodeling, suggesting that inhibiting structural remodeling may also be a protective effect of PPARγ in cerebral vasculature. Thus, the role of PPARγ in the cerebral circulation appears similar to that of pregnancy, including enhanced NO-dependent dilation and inhibition of structural remodeling. Considering PPARγ is highly activated during pregnancy, we hypothesized that PPARγ activity is involved in the vascular adaptation to pregnancy in the cerebral circulation. To test this hypothesis, pregnant and non-pregnant (NP) rats were treated with GW9662, a specific PPARγ inhibitor that acts through cysteine modification in the ligand-binding site of PPARγ (Leesnitzer et al., [@B24]). We investigated the effect of PPARγ inhibition during pregnancy on NO-mediated dilation, myogenic activity, and structural characteristics of posterior cerebral arteries (PCA). In addition, gene expression of PPARγ and angiotensin type 1 receptor (AT1R) were determined in cerebral arteries because of the potential involvement of these receptors in vascular function and remodeling during pregnancy (Cox et al., [@B16]).

Materials and Methods
=====================

Animals and treatment groups
----------------------------

Pregnant (6--8 days pregnant) and NP (12--14 weeks old) Sprague Dawley rats (Charles River, Canada) were housed in the University of Vermont Animal Care Facility. Animals were randomly selected and treated with either GW9662 (10 mg/kg/day for 10 days in food; *n* = 8) or vehicle (*n* = 8). This dose of GW9662 was higher than has been reported in other studies (Sivarajah et al., [@B35]) due to the higher activation of PPARγ in pregnancy (Waite et al., [@B38]). Rats were studied on day 20 or 21 of pregnancy. There was one NP rat that did not consume GW9662, and thus was excluded from the study and all comparisons. All procedures were approved by the Institutional Animal Care and Use Committee and conducted in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals.

Blood pressure and glucose measurements
---------------------------------------

Blood pressures were measured non-invasively every 2--3 days during GW9662 treatment by determining the tail blood volume with a volume pressure recording sensor and an occlusion tail cuff (Coda 8 System, Kent Scientific, Torrington, CT, USA), as previously described (Cipolla et al., [@B12]). Briefly, the animals were placed in individual holders and both the occlusion cuff and the volume pressure recording cuff were secured close to the base of the tail. The Coda 8 system measures systolic, diastolic, and mean blood pressures. Blood samples were collected from the tail of conscious rats for blood glucose measurement on the last day of the treatment, prior to euthanization (FreeStyle Lite, Abbott Inc., Alameda, CA, USA).

Vessel preparation and pressurized arteriograph system
------------------------------------------------------

Animals were anesthetized with isoflurane (3% in oxygen), decapitated, and the brain was quickly removed and placed in cold HEPES-buffered physiological salt solution. A third-order branch of the PCA was carefully isolated and mounted on glass cannulas in an arteriograph chamber, the proximal cannula of which was connected to an in-line pressure transducer and a servo-null pressure control system (Living Systems Instrumentation, Burlington, VT, USA). The distal cannula was closed during the experiment to avoid flow-mediated responses. Temperature and pH were continually measured and maintained at 37.0 ± 0.5°C and 7.40 ± 0.05, respectively. Measurements of inner diameter (ID) and wall thickness (WT) were made via video microscopy (Living Systems Instrumentation, Burlington, VT, USA). The remaining cerebral pial vessels were dissected from the brain, collected in RNAlater (Qiagen Inc, Valencia, CA, USA) and rapidly frozen for PCR analysis.

Experimental protocol
---------------------

Arteries were equilibrated for 1 h at 25 mmHg. Active myogenic activity was determined by stepwise increases in pressure (in 25 mmHg increments) from 25 to 175 mmHg and ID measured at each pressure. To obtain agonist-induced vasodilatory responses, pressure was returned to 75 mmHg until tone developed and diameter stabilized. Arteries were then exposed to cumulative concentrations of ACh (10^−8^--10^−5^ M) and ID recorded at each concentration once stable. ACh was then washed from the bath and SNP (10^−8^--10^−5^ M) was cumulatively added and ID recorded. To obtain structural measurements, ID and WT were recorded at pressures between 5 to 175 mmHg after papaverine (10^−4^ M) and diltiazem (10^−5^ M) were added to the bath to fully relax smooth muscle.

Real-time RT-PCR analysis of target genes in pial vessels
---------------------------------------------------------

Gene expression of PPARγ and AT1R were determined in cerebral vessels using standard techniques for real-time RT-PCR, as described previously (Cipolla et al., [@B13]). These procedures were performed by the DNA facility at the University of Vermont. Results were calculated by the 2^−ΔΔCT^ method (Livak and Schmittgen, [@B25]). The percent change in gene expression was normalized to an endogenous gene (β~2~-microglobulin, B2M) and relative to the untreated NP group.

Drugs and solutions
-------------------

ACh, SNP, papaverine, and diltiazem were purchased from Sigma (St. Louis, MO, USA). Drugs were made as stock solutions each week and stored at 4°C. GW9662 was purchased from Cayman Chemical (Ann Arbor, MI, USA). All vessel experiments were performed in physiological salt solutions containing the following (in mM): 142.0 NaCl, 4.7 KCl, 1.2 MgSO~4~, 0.5 EDTA, 2.8 CaCl~2~, 10.0 HEPES, 1.2 KH~2~PO~4~, and 5.0 glucose.

Data calculations and statistical analysis
------------------------------------------

Percent tone was calculated as percent decrease in ID from the passive diameter at each intravascular pressure: \[1 − (ID~active~/ID~passive~)\] × 100%. Outer diameter (OD) was calculated from measured ID and WT: ID + 2WT. Wall-to-lumen ratio was calculated as: ID/WT. Cross-sectional area (CSA) of the wall was calculated as: \[(0.5 × OD)^2^ − (0.5 × ID)^2^\] × π. Passive distensibility was calculated as the percent change in ID at a given pressure (ID~p~) from the original diameter (ID~o~, at 5 mmHg): \[(ID~p~ − ID~o~)/ID~o~\] × 100%.

All data are presented as mean ± SEM. Differences between individual groups were compared with one-way analysis of variance (ANOVA) with *post hoc* Student--Newman--Keuls Multiple Comparison Test, using Graph Pad Prism 5 (Graph Pad Software Inc., La Jolla, CA, USA). It was anticipated that pregnancy would alter responses to GW9662, thus two-way ANOVA was used to compare two independent variables GW9662 treatment and pregnancy, and their interaction. Differences were considered significant when *p* \< 0.05.

Results
=======

Physiological parameters
------------------------

Physiological parameters for all groups of animals are shown in Table [1](#T1){ref-type="table"}. Pregnancy significantly decreased blood glucose compared to the untreated NP group. GW9662 increased blood glucose in NP rats but had no effect on late-pregnant (LP) rats. Pregnancy decreased mean arterial pressure compared to untreated NP rats. GW9662 treatment decreased mean arterial pressure in NP rats, but did not further affect blood pressure in LP rats. As expected, body weights were significantly increased in LP rats. GW9662 did not affect body weights of either NP or LP rats.

###### 

**Physiological parameters of non-pregnant (NP), NP treated with GW9662 (NP + GW), late-pregnant (LP), and LP treated with GW9662 (LP + GW)**.

                                  NP (*n* = 8)   NP + GW (*n* = 7)   LP (*n* = 8)   LP + GW (*n* = 8)
  ------------------------------- -------------- ------------------- -------------- -------------------
  Body weights (g)                308 ± 4        306 ± 5             384 ± 7\*      381 ± 5\*
  Blood glucose (mg/dl)           109 ± 3        132 ± 9\*           88 ± 5\*       91 ± 4†
  Mean arterial pressure (mmHg)   105 ± 3        92 ± 4\*            92 ± 4\*       87 ± 3\*

*Data are presented as means ± SEM*.

*\*p \< 0.05 vs. NP; †p \< 0.05 vs. NP + GW*.

Effects of GW9662 during pregnancy on tone and myogenic activity
----------------------------------------------------------------

Figure [1](#F1){ref-type="fig"} shows percent tone in PCA at 75 mmHg from all groups. GW9662 treatment tended to increase tone in PCA from NP rats (44 ± 3% vs. 30 ± 6% in control, *p* = 0.08), but had no effect in PCA from LP rats. Figure [2](#F2){ref-type="fig"} shows active internal diameters versus intraluminal pressure for all groups of animals. Most PCA constricted when pressure increased from 25 to 75 mmHg, demonstrating active myogenic activity that was sustained until 175 mmHg (Figures [2](#F2){ref-type="fig"}A,B). At 175 mmHg, there was a dramatic increase in ID as arteries underwent forced dilatation. PCA from GW9662-treated NP rats had smaller ID at all pressures when compared to untreated NP rats, although this was not statistically significant (Figure [2](#F2){ref-type="fig"}A). The decreased ID was particularly obvious at 75 and 100 mmHg (decreased by 23% and 24%, respectively) when compared to untreated NP rats. This smaller ID may be due to increased tone by GW9662 treatment. In contrast to NP rats, GW9662 treatment did not decrease ID, but rather tended to increase ID of PCA at all pressures from LP rats, although this was not statistically significant.

![**Graph showing percent tone of PCA at intraluminal pressure of 75 mmHg from non-pregnant (NP), NP treated with the PPARγ inhibitor GW9622 (NP + GW), late-pregnant (LP), LP treated with GW9662 (LP + GW)**. PPARγ inhibition tended to increase tone in NP-GW rats (*p* = 0.08), but had no effect on pregnant rats.](fphys-01-00130-g001){#F1}

![**Graph showing active internal diameters versus intraluminal pressure of PCA in (A) non-pregnant (NP) and GW9662-treated NP (NP + GW) groups; (B) late-pregnant (LP) and GW9662-treated LP (LP + GW) groups**. Myogenic activity in PCA was demonstrated by constriction in response to increases in pressure and tended to be increased in NP-GW but not in PCA from LP or LP-GW rats.](fphys-01-00130-g002){#F2}

Effects of GW9662 during pregnancy on ACh- and SNP-induced dilation
-------------------------------------------------------------------

In the GW9662-treated NP group, four experiments were excluded because there were three PCA that either did not develop basal tone or maximally dilated prematurely during ACh exposure. In addition, there was one PCA in each untreated NP and LP group that did not develop tone, and thus were excluded. These explain the inconsistent and low number in GW9662-treated NP group (*n* = 4).

Figure [3](#F3){ref-type="fig"}A shows the concentration-response relationship of ACh-induced dilation. GW9662 inhibited ACh-induced dilation in PCA from NP rats but did not affect the response to ACh in PCA from LP rats. Two-way ANOVA revealed that dilator responses to ACh (from 3 × 10^−7^ to 10^−5^ M) in PCA from NP-GW rats were significantly different from that of LP-GW rats. This difference was likely due to absence of dilation to ACh in PCA from NP-GW rats because GW9662 did not impact ACh-induced dilation in PCA from LP rats.

![**Graph showing percent dilation of PCA in response to (A) ACh (10^−8^--10^−5^ M) and (B) SNP (10^−8^--10^−5^ M) from non-pregnant (NP), NP treated with the PPARγ inhibitor GW9622 (NP + GW), late-pregnant (LP), LP treated with GW9662 (LP + GW)**. Note that two-way ANOVA revealed that dilation to ACh (3 × 10^−7^--10^−5^ M) and SNP (10^−7^--10^−5^ M) in PCA from NP + GW rats was significantly different from that of LP + GW rats. \**p* \< 0.05 vs. LP + GW.](fphys-01-00130-g003){#F3}

Figure [3](#F3){ref-type="fig"}B shows the concentration-response of SNP-induced dilation for all groups of animals. GW9662 treatment decreased the dilator response to SNP in PCA from NP rats, although this was not statistically significant, likely due to the small sample size in NP-GW group. Similar to the dilator response to ACh, two-way ANOVA revealed that dilator responses to SNP (from 10^−7^ to 10^−5^ M) in PCA from NP-GW rats were significantly different from that of LP-GW rats. Dilation to SNP in PCA from NP-GW rats was the main contributor to the difference, because GW9662 did not affect dilation to SNP in PCA from LP rats.

Effects of GW9662 during pregnancy on vascular structure in PCA
---------------------------------------------------------------

To examine structural changes of PCA in response to pregnancy and GW9662 treatment, we measured ID and WT in fully relaxed PCA (by papaverine and diltiazem) at 5 mmHg. Measurements were made at minimal pressure (5 mmHg) to avoid vessel collapse and eliminate differences due to changes in distensibility. OD, wall-to-lumen ratios, and CSA were also calculated. WT was significantly increased in PCA from GW9662-treated NP rats (Table [2](#T2){ref-type="table"}). Compared to untreated NP rats, PCA from NP-GW rats had only a small decrease in ID. Thus, the increased WT was the major contributor to the increased wall-to-lumen ratio. GW9662-induced hypertrophy in PCA from NP rats was confirmed by increased CSA. Moreover, similar increases in WT were observed in PCA from LP-GW rats with increased wall-to-lumen ratio and CSA. Two-way ANOVA revealed that GW9662 treatment significantly altered WT, wall-to-lumen ratio, and CSA compared to untreated NP and LP rats. Compared to untreated LP rats, hypertrophy in PCA from LP-GW rats contributed to an increase in OD because ID was similar. These results suggest that PPARγ inhibition caused inward hypertrophic remodeling in PCA from NP rats, but outward hypertrophic remodeling in PCA from LP rats.

###### 

**Passive structural measurements of cerebral posterior arteries in non-pregnant (NP), NP treated with GW9662 (NP + GW), late-pregnant (LP), and LP treated with GW9662 (LP + GW) at 5 mmHg**.

                        NP (*n* = 8)    NP + GW (*n* = 7)                               LP (*n* = 8)    LP + GW (*n* = 8)
  --------------------- --------------- ----------------------------------------------- --------------- -----------------------------------------------
  Inner diameter (μm)   127 ± 5         117 ± 2                                         121 ± 3         121 ± 4
  Outer diameter (μm)   168 ± 5         166 ± 2                                         164 ± 4         170 ± 5
  Wall thickness (μm)   20.5 ± 0.8      24.3 ± 0.8[\*](#tfn1){ref-type="table-fn"}      21.9 ± 0.9      24.1 ± 1.1[\*](#tfn1){ref-type="table-fn"}
  Wall-to-lumen ratio   0.162 ± 0.008   0.208 ± 0.009[\*](#tfn1){ref-type="table-fn"}   0.182 ± 0.008   0.199 ± 0.008[\*](#tfn1){ref-type="table-fn"}
  CSA (μm^2^)           9542 ± 535      10786 ± 355[\*](#tfn1){ref-type="table-fn"}     9817 ± 569      11093 ± 736[\*](#tfn1){ref-type="table-fn"}

*Data are presented as means* ± *SEM*.

*CSA, cross-sectional area*.

\**p* \< *0.05 vs. NP*

To further examine structural changes of the vessel wall in response to pregnancy and GW9662 treatment, we calculated passive distensibility at various intraluminal pressures. Figure [4](#F4){ref-type="fig"} shows passive distensibility from all groups of animals. GW9662 treatment significantly increased distensibility at pressures of 30, 40, 50 mmHg in PCA from NP rats (Figure [4](#F4){ref-type="fig"}A) but did not affect distensibility of PCA from LP rats (Figure [4](#F4){ref-type="fig"}B). In addition, compared to NP rats, distensibility was increased at 30, 40, 50, 75 mmHg in PCA from LP rats (Figure [4](#F4){ref-type="fig"}C). The effect of GW9662 treatment on distensibility was similar in PCA from NP and LP rats (Figure [4](#F4){ref-type="fig"}D).

![**Graph showing passive distensibility versus intraluminal pressure of PCA in (A) non-pregnant (NP) and GW9662-treated NP (NP + GW) groups; (B) late-pregnant (LP) and GW9662-treated LP (LP + GW) groups; (C) NP and LP groups; and (D) NP + GW and LP + GW groups**. \**p* \< 0.05: NP vs. NP + GW; †*p* \< 0.05: NP vs. LP.](fphys-01-00130-g004){#F4}

Effects of GW9662 and pregnancy on target gene expression
---------------------------------------------------------

Relative mRNA expression of PPARγ in cerebral vessels was significantly decreased during pregnancy regardless of GW9662 treatment (Figure [5](#F5){ref-type="fig"}A). GW9662 did not change the expression of PPARγ in cerebral vessels from NP or LP rats. Messenger RNA expression of AT1R expression was significantly decreased in cerebral vessels from LP rats, but was also unaffected by GW9662 treatment in cerebral vessels from NP or LP rats (Figure [5](#F5){ref-type="fig"}B).

![**Graph showing relative changes in mRNA expression of (A) PPARγ and (B) angiotensin type 1 receptors (AT1R) in cerebral vessels of non-pregnant (NP), NP + GW9662 (NP + GW), late-pregnant (LP), and LP + GW9662 (LP + GW) groups**. Results are presented as percent change in gene expression normalized to β2-microglobulin (B2M), an endogenous reference gene, and relative to the untreated NP group (*n* = 7--8, mean ± SEM). Expression of PPARγ and AT1R was decreased in cerebral vessels from LP rats but unaffected by GW9662 treatment. \**p* \< 0.05 vs. NP, †*p* \< 0.05 vs. NP + GW.](fphys-01-00130-g005){#F5}

Discussion
==========

There are several novel findings in the present study. First, PPARγ inhibition with GW9662 abolished dilation to ACh and reduced the dilatory response to SNP in PCA from NP rats, suggesting that PPARγ inhibition may cause endothelial dysfunction and reduced smooth muscle responsiveness to NO. However, PPARγ inhibition had no effect on the dilation to ACh and SNP in PCA from LP rats. Second, PPARγ inhibition tended to increase basal tone and myogenic activity in PCA from NP rats. These effects were not seen in PCA from LP rats. Third, PPARγ inhibition increased WT, wall-to-lumen ratio, CSA, and passive distensibility in PCA from NP rats. A small decrease in ID was associated with increased WT, suggesting inward remodeling in these vessels. PPARγ inhibition also increased WT and CSA in PCA from LP rats. However, a small increase in OD was observed in these vessels, suggesting outward remodeling. Lastly, gene expression of PPARγ and AT1R in cerebral vessels were decreased in LP rats regardless of GW9662 treatment. In summary, PPARγ inhibition caused vascular dysfunction and inward remodeling in cerebral arteries from NP animals, but had little effect during pregnancy except to promote modest outward remodeling.

There may be several reasons why GW9662 treatment had little effect on physiological parameters and vascular function in PCA from LP rats. First, pregnancy significantly decreased (by 85%) gene expression of PPARγ, regardless of GW9662 treatment. It is therefore possible that further inhibition of PPARγ that was already highly down-regulated during pregnancy was not efficacious. Second, it is possible that treatment with GW9662 during pregnancy was too mild to have a significant effect. Because we were concerned about PPARγ inhibition interfering with implantation and establishment of pregnancy, we treated animals during the second half of pregnancy. PPARγ inhibition may have had a greater influence if treatment with GW9662 was started in early pregnancy or even prior to pregnancy. In addition, the dose of GW9662 used may not have been high enough to inhibit PPARγ in late-pregnancy when PPARγ is highly activated (Waite et al., [@B37]). Lastly, PPARγ may still be activated during pregnancy even in the presence of GW9662. Relaxin, a hormone circulating at high concentration during pregnancy, has been shown to activate PPARγ through a non-receptor-mediated mechanism (Singh and Bennett, [@B34]). Thus, it is possible that other non-receptor-mediated effects of PPARγ may still be present because GW9662 only inhibited receptor-mediated actions of PPARγ.

PPARγ has been shown to have a significant beneficial role in protecting the vasculature, especially with regards to endothelial function. Genetic interference with PPARγ function has been shown to decrease ACh-induced dilation in cerebral vessels of male mice (Beyer et al., [@B6]), suggesting PPARγ activity is important for normal endothelial function in the cerebral circulation. In the present study, PPARγ inhibition with GW9662 treatment decreased ACh and SNP dilation in PCA from NP rats, which is in partial agreement with a previous study (Beyer et al., [@B6]). Although this previous study did not find an effect of PPARγ on dilation to SNP, another study has shown that interference with PPARγ decreased dilation to SNP in aorta (Halabi et al., [@B20]). Together, these results suggest that PPARγ inhibition with GW9662 impacts NO-mediated dilation in both endothelium and smooth muscle in males and NP females. However, NO responsiveness was unaffected when PPARγ was inhibited during pregnancy, possibly due to a pregnancy-specific adaptation such as decreased PPARγ expression or a difference in treatment efficacy.

An important function of cerebral arteries is that they constrict or dilate in response to increases or decreases in pressure, respectively. This myogenic activity is well-developed in the brain circulation and underlies autoregulation of cerebral blood flow (Johnson, [@B22]). In the present study, we tested how PPARγ inhibition during pregnancy affected tone and myogenic activity in PCA. Pregnancy alone did not change basal tone in PCA at physiological pressures (75 mmHg), which is similar to our previous study (Cipolla et al., [@B14]). PPARγ inhibition tended to increase tone in PCA from NP rats, but not in PCA from LP rats. The increased tone in NP-GW rats may be due to reduced endothelium-dependent vasodilator production as ACh responses were abolished in those animals, however, we did not directly examine the effect of PPARγ inhibition on basal endothelial vasodilator release. In addition, as dilation to SNP was also decreased in PCA from NP-GW rats, it is possible that the smooth muscle response to vasodilator was also affected by PPARγ inhibition. In addition, PCA from all groups developed myogenic activity as demonstrated by active constriction in response to increases in pressure. Pregnancy did not significantly change myogenic activity within the myogenic pressure range, which agrees with our previous study (Cipolla et al., [@B14]). Moreover, PPARγ inhibition with GW9662 appeared to increase myogenic activity at lower pressures (50, 75 mmHg) in PCA from NP rats, but did not seem to affect myogenic activity from LP rats. Although PPARγ appeared to be involved in regulating tone and myogenic activity in the NP state possibly through endothelium or smooth cell effects, the results from the present study suggest that PPARγ appears to have little effect on basal tone and myogenic activity in cerebral vasculature during pregnancy.

One of the most profound influences of PPARγ in the vasculature is on structural remodeling. Some studies have shown that PPARγ is involved in vascular remodeling in cerebral vessels in male rats (Beyer et al., [@B6]; Halabi et al., [@B20]). Pregnancy also has a significant effect in cerebral artery remodeling, especially during hypertension, that is similar to those attributed to PPARγ. For example, hypertension can cause inward remodeling in the cerebral vasculature (Baumbach et al., [@B2]) and pregnancy has been shown to both prevent and reverse hypertensive remodeling in PCA (Cipolla et al., [@B11], [@B10]). In a recent study, similar prevention of hypertensive remodeling of PCA from NP rats was shown in response to PPARγ activation (Cipolla et al., [@B9]). In the present study, we determined if PPARγ activity during pregnancy impacted structural remodeling in cerebral arteries. PPARγ inhibition caused hypertrophy in PCA from both NP and LP rats, as evidenced by increased WT and CSA. These results suggest that PPARγ may have a role in suppressing smooth muscle growth and migration (Meredith et al., [@B27]). Interestingly, the remodeling in PCA from NP rats appeared to be different from that of PCA from LP rats. For example, PPARγ inhibition caused inward hypertrophic remodeling in PCA from NP rats but outward hypertrophic remodeling in PCA from LP rats. The differential response to PPARγ inhibition in NP and LP rats is not clear, but may involve pregnancy-induced decrease in AT1R in the cerebral vasculature. Angiotensin II has a significant role in remodeling in cerebral vasculature (Baumbach et al., [@B3]; Dupuis et al., [@B17]) through NADPH oxidase-derived superoxide and not hypertension *per se* (Chan and Baumbach, [@B8]). This effect of angiotensin II is largely through the activation of AT1R (Griendling et al., [@B19]). A previous study showed that inward remodeling of cerebral arterioles induced by interference with PPARγ function involved increased superoxide (Beyer et al., [@B6]). Moreover, PPARγ activation suppresses AT1R in vascular smooth muscle cells (Takeda et al., [@B36]) and inhibits the signaling involved in angiotensin II-mediated vascular remodeling (Benkirane et al., [@B4]). Thus, it is possible that inhibition of PPARγ in NP rats, without increased blood pressure, may lead to increased oxidative stress and the loss of suppression to AT1R-mediated inward remodeling. However, this inward remodeling was not seen in PCA from LP rats, possibly due to pregnancy-induced down-regulation of AT1R expression.

Changes in vascular WT and extracellular matrix components alter vascular wall distensibility in cerebral vessels (Baumbach et al., [@B2]). Thus, we examined how vascular remodeling induced by PPARγ inhibition during pregnancy affected passive distensibility of PCA. PPARγ inhibition increased passive distensibility in PCA from NP rats that may be due to smooth muscle growth (hypertrophy) induced by PPARγ inhibition. In smaller resistance vessels such as the PCA, smooth muscle is relatively more abundant and contributes more significantly to the compliance of the wall than that of larger vessels, in which collagen is the major determinant of vascular stiffness (Baumbach et al., [@B2]). In contrast, passive distensibility was increased in PCA from untreated LP rats, which was not further affected by PPARγ inhibition. It is worth noting that, compared to NP rats, PCA from untreated LP rats increased distensibility without increases in WT and CSA, suggesting that the increased distensibility was not due to smooth muscle growth that was observed in the GW9662-treated NP rats. The increased distensibility in PCA from LP rats may be due to changes in extracellular matrix components of the vessel wall, such as collagen and elastin, which has been shown in mesenteric arteries during pregnancy (Mackey et al., [@B26]). These results suggest that both PPARγ inhibition and pregnancy increase passive distensibility, but may involve changes in different vascular wall components.

In conclusion, PPARγ inhibition appears to have little impact on the function and structure of cerebral vasculature during pregnancy. This lack of an effect of PPARγ inhibition in cerebral vasculature may be due, at least in part, to down-regulation of PPARγ and AT1R in cerebral arteries during pregnancy. Changes in expression of PPARγ and AT1R suggest that effects of PPARγ and AT1R may be suppressed in the cerebral vasculature, despite their importance in vascular function and structure in other organs during pregnancy. The resulting effect may make the cerebral circulation less responsive to circulating factors and promote constant hemodynamics in the brain during pregnancy.
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